Gracell Biotechnologies

Developer of cancer immune therapy designed to treat cancer

Stránky společnosti

Ticker

GRCL.NASDAQ

Trh

Rok založení

2017

Uzávěrka

2/10/2021

Datum IPO

1/7/2021

Cena umístění

$19

Ziskovost

54.95%

O společnosti

Total Funding

$185M

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.

Number of employees

51-100

Headquarters

Suzhou, Jiangsu, China